[Form 4] Guardant Health, Inc. Insider Trading Activity
Steve E. Krognes, a director of Guardant Health, Inc. (GH), reported acquisitions on Form 4 dated 08/31/2025. The filing shows a non-derivative entry and a derivative entry reflecting restricted stock units. The non-derivative entry records 155 shares acquired on 08/31/2025 at an aggregate price of $0, bringing his direct beneficial ownership of common stock to 18,128 shares. The derivative section shows 155 restricted stock units reported on 08/31/2025 with a $0 price, corresponding to 1,543 shares of common stock beneficially owned following the transaction on a direct basis. Explanatory notes state the RSU award was granted on August 9, 2022, with 25% vesting on June 30, 2023 and the remaining 75% vesting in substantially equal monthly installments over the following three years.
Steve E. Krognes, membro del consiglio di Guardant Health, Inc. (GH), ha dichiarato acquisizioni nel Modulo 4 datato 31/08/2025. La comunicazione riporta una voce non derivata e una voce derivata relative a unit脿 azionarie vincolate (RSU). La voce non derivata indica l'acquisto di 155 azioni il 31/08/2025 a un prezzo complessivo di $0, portando la sua propriet脿 diretta di azioni ordinarie a 18.128 azioni. Nella sezione derivata sono segnalate 155 RSU il 31/08/2025 a prezzo $0, corrispondenti a 1.543 azioni di azioni ordinarie di cui beneficia direttamente dopo la transazione. Le note esplicative precisano che l'assegnazione delle RSU risale al 9 agosto 2022, con il 25% maturato il 30 giugno 2023 e il restante 75% che matura in rate mensili sostanzialmente uguali nei tre anni successivi.
Steve E. Krognes, director de Guardant Health, Inc. (GH), declar贸 adquisiciones en el Formulario 4 con fecha 31/08/2025. La presentaci贸n muestra una entrada no derivada y una entrada derivada relativa a unidades restringidas de acciones (RSU). La entrada no derivada registra la adquisici贸n de 155 acciones el 31/08/2025 a un precio agregado de $0, elevando su propiedad directa de acciones ordinarias a 18.128 acciones. En la secci贸n derivada se informan 155 RSU el 31/08/2025 con precio $0, equivalentes a 1.543 acciones de acciones ordinarias de las que es beneficiario directo tras la transacci贸n. Las notas explicativas indican que la concesi贸n de RSU se otorg贸 el 9 de agosto de 2022, con un 25% que adquiri贸 derechos el 30 de junio de 2023 y el 75% restante que se ir谩 consolidando en cuotas mensuales sustancialmente iguales durante los tres a帽os siguientes.
Guardant Health, Inc. (GH) 鞚挫偓鞚� Steve E. Krognes電� 2025雲� 8鞗� 31鞚检瀽 Form 4鞐� 旆摑 靷嫟鞚� 鞁犼碃頄堨姷雼堧嫟. 頃措嫻 鞁犼碃鞐愲姅 牍勴寣靸� 頃瓿� 鞝滍暅欤检嫕雼渼(RSU)毳� 氚橃榿頃� 韺岇儩 頃鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 牍勴寣靸� 頃鞐愲姅 2025雲� 8鞗� 31鞚检棎 155欤�毳� 齑濎暋 $0鞐� 旆摑頃� 瓴冹溂搿� 旮半霅橃柎 攴胳潣 氤错喌欤� 歆侅爲 氤挫湢 歆�攵勳澊 18,128欤�臧� 霅橃棃鞀惦媹雼�. 韺岇儩 靹轨厴鞐愲姅 2025雲� 8鞗� 31鞚检瀽搿� 臧�瓴� $0鞚� 155 RSU臧� 鞁犼碃霅橃柎 鞛堨溂氅�, 鞚措姅 瓯半灅 頉� 歆侅爲鞝侅溂搿� 1,543欤�鞚� 氤错喌欤检棎 頃措嫻頃╇媹雼�. 靹る獏 雲疙姼鞐愲姅 RSU 靾橃棳鞚检澊 2022雲� 8鞗� 9鞚检澊氅� 25%電� 2023雲� 6鞗� 30鞚检棎 氩犾姢韺呺悩瓿� 雮橂ǜ歆� 75%電� 鞚错泟 3雲� 霃欖晥 瓯办潣 霃欖澕頃� 鞗旊硠 攵勴暊搿� 氩犾姢韺呺悳雼り碃 鞝來榾 鞛堨姷雼堧嫟.
Steve E. Krognes, administrateur de Guardant Health, Inc. (GH), a d茅clar茅 des acquisitions sur le formulaire 4 dat茅 du 31/08/2025. le d茅p么t indique une entr茅e non d茅riv茅e et une entr茅e d茅riv茅e refl茅tant des unit茅s d'actions restreintes (RSU). L'entr茅e non d茅riv茅e enregistre 155 actions acquises le 31/08/2025 pour un prix global de 0 $, portant sa d茅tention directe d'actions ordinaires 脿 18 128 actions. La section d茅riv茅e mentionne 155 RSU d茅clar茅es le 31/08/2025 脿 prix 0 $, correspondant 脿 1 543 actions ordinaires dont il est b茅n茅ficiaire direct apr猫s la transaction. Les notes explicatives pr茅cisent que l'attribution des RSU a 茅t茅 effectu茅e le 9 ao没t 2022, avec 25 % acquise le 30 juin 2023 et les 75 % restants acqu茅rant droit par mensualit茅s sensiblement 茅gales sur les trois ann茅es suivantes.
Steve E. Krognes, ein Direktor von Guardant Health, Inc. (GH), meldete Erwerbe in Formular 4 vom 31.08.2025. Die Einreichung enth盲lt einen nicht-derivaten Posten und einen derivaten Posten, der Restricted Stock Units (RSU) abbildet. Der nicht-derivate Posten verzeichnet 155 erworbene Aktien am 31.08.2025 zu einem Gesamtpreis von $0 und erh枚ht damit seinen direkten wirtschaftlichen Eigentum an Stammaktien auf 18.128 Aktien. Der derivative Abschnitt weist 155 RSU aus, gemeldet am 31.08.2025 zu $0, was nach der Transaktion direkt 1.543 Aktien an Stammaktien entspricht. Erl盲uternde Hinweise geben an, dass die RSU-Zuweisung am 9. August 2022 erfolgte, 25% am 30. Juni 2023 vesteten und die verbleibenden 75% 眉ber die folgenden drei Jahre in im Wesentlichen gleichen monatlichen Raten vesten.
- None.
- None.
Insights
TL;DR: Routine RSU vesting increases director's direct ownership by 155 units; no cash paid and no sale activity reported.
The Form 4 documents a non-cash acquisition of 155 restricted stock units reflected as both a non-derivative and derivative entry, consistent with standard equity compensation vesting. The disclosed figures鈥�18,128 shares direct ownership and 1,543 derivative shares beneficially owned following the transaction鈥攁re purely ownership updates and do not indicate changes in company operations, liquidity, or capital structure. This filing should be interpreted as an insider compensation/ownership disclosure rather than an economic trade signal.
TL;DR: Director reported RSU vesting per prior grant terms; disclosure aligns with Section 16 reporting requirements.
The explanatory note clarifies the RSU grant date (August 9, 2022) and vesting schedule (25% vested June 30, 2023; remainder vesting monthly over three years), which supports transparency about executive/director equity incentives. The filing was signed by an attorney-in-fact, consistent with authorized agent reporting practices. There are no indications of unusual related-party transactions or departures from standard governance disclosure norms in this Form 4.
Steve E. Krognes, membro del consiglio di Guardant Health, Inc. (GH), ha dichiarato acquisizioni nel Modulo 4 datato 31/08/2025. La comunicazione riporta una voce non derivata e una voce derivata relative a unit脿 azionarie vincolate (RSU). La voce non derivata indica l'acquisto di 155 azioni il 31/08/2025 a un prezzo complessivo di $0, portando la sua propriet脿 diretta di azioni ordinarie a 18.128 azioni. Nella sezione derivata sono segnalate 155 RSU il 31/08/2025 a prezzo $0, corrispondenti a 1.543 azioni di azioni ordinarie di cui beneficia direttamente dopo la transazione. Le note esplicative precisano che l'assegnazione delle RSU risale al 9 agosto 2022, con il 25% maturato il 30 giugno 2023 e il restante 75% che matura in rate mensili sostanzialmente uguali nei tre anni successivi.
Steve E. Krognes, director de Guardant Health, Inc. (GH), declar贸 adquisiciones en el Formulario 4 con fecha 31/08/2025. La presentaci贸n muestra una entrada no derivada y una entrada derivada relativa a unidades restringidas de acciones (RSU). La entrada no derivada registra la adquisici贸n de 155 acciones el 31/08/2025 a un precio agregado de $0, elevando su propiedad directa de acciones ordinarias a 18.128 acciones. En la secci贸n derivada se informan 155 RSU el 31/08/2025 con precio $0, equivalentes a 1.543 acciones de acciones ordinarias de las que es beneficiario directo tras la transacci贸n. Las notas explicativas indican que la concesi贸n de RSU se otorg贸 el 9 de agosto de 2022, con un 25% que adquiri贸 derechos el 30 de junio de 2023 y el 75% restante que se ir谩 consolidando en cuotas mensuales sustancialmente iguales durante los tres a帽os siguientes.
Guardant Health, Inc. (GH) 鞚挫偓鞚� Steve E. Krognes電� 2025雲� 8鞗� 31鞚检瀽 Form 4鞐� 旆摑 靷嫟鞚� 鞁犼碃頄堨姷雼堧嫟. 頃措嫻 鞁犼碃鞐愲姅 牍勴寣靸� 頃瓿� 鞝滍暅欤检嫕雼渼(RSU)毳� 氚橃榿頃� 韺岇儩 頃鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 牍勴寣靸� 頃鞐愲姅 2025雲� 8鞗� 31鞚检棎 155欤�毳� 齑濎暋 $0鞐� 旆摑頃� 瓴冹溂搿� 旮半霅橃柎 攴胳潣 氤错喌欤� 歆侅爲 氤挫湢 歆�攵勳澊 18,128欤�臧� 霅橃棃鞀惦媹雼�. 韺岇儩 靹轨厴鞐愲姅 2025雲� 8鞗� 31鞚检瀽搿� 臧�瓴� $0鞚� 155 RSU臧� 鞁犼碃霅橃柎 鞛堨溂氅�, 鞚措姅 瓯半灅 頉� 歆侅爲鞝侅溂搿� 1,543欤�鞚� 氤错喌欤检棎 頃措嫻頃╇媹雼�. 靹る獏 雲疙姼鞐愲姅 RSU 靾橃棳鞚检澊 2022雲� 8鞗� 9鞚检澊氅� 25%電� 2023雲� 6鞗� 30鞚检棎 氩犾姢韺呺悩瓿� 雮橂ǜ歆� 75%電� 鞚错泟 3雲� 霃欖晥 瓯办潣 霃欖澕頃� 鞗旊硠 攵勴暊搿� 氩犾姢韺呺悳雼り碃 鞝來榾 鞛堨姷雼堧嫟.
Steve E. Krognes, administrateur de Guardant Health, Inc. (GH), a d茅clar茅 des acquisitions sur le formulaire 4 dat茅 du 31/08/2025. le d茅p么t indique une entr茅e non d茅riv茅e et une entr茅e d茅riv茅e refl茅tant des unit茅s d'actions restreintes (RSU). L'entr茅e non d茅riv茅e enregistre 155 actions acquises le 31/08/2025 pour un prix global de 0 $, portant sa d茅tention directe d'actions ordinaires 脿 18 128 actions. La section d茅riv茅e mentionne 155 RSU d茅clar茅es le 31/08/2025 脿 prix 0 $, correspondant 脿 1 543 actions ordinaires dont il est b茅n茅ficiaire direct apr猫s la transaction. Les notes explicatives pr茅cisent que l'attribution des RSU a 茅t茅 effectu茅e le 9 ao没t 2022, avec 25 % acquise le 30 juin 2023 et les 75 % restants acqu茅rant droit par mensualit茅s sensiblement 茅gales sur les trois ann茅es suivantes.
Steve E. Krognes, ein Direktor von Guardant Health, Inc. (GH), meldete Erwerbe in Formular 4 vom 31.08.2025. Die Einreichung enth盲lt einen nicht-derivaten Posten und einen derivaten Posten, der Restricted Stock Units (RSU) abbildet. Der nicht-derivate Posten verzeichnet 155 erworbene Aktien am 31.08.2025 zu einem Gesamtpreis von $0 und erh枚ht damit seinen direkten wirtschaftlichen Eigentum an Stammaktien auf 18.128 Aktien. Der derivative Abschnitt weist 155 RSU aus, gemeldet am 31.08.2025 zu $0, was nach der Transaktion direkt 1.543 Aktien an Stammaktien entspricht. Erl盲uternde Hinweise geben an, dass die RSU-Zuweisung am 9. August 2022 erfolgte, 25% am 30. Juni 2023 vesteten und die verbleibenden 75% 眉ber die folgenden drei Jahre in im Wesentlichen gleichen monatlichen Raten vesten.
FAQ
What did Guardant Health director Steve Krognes report on Form 4 (GH)?
How many Guardant Health (GH) shares does Steve Krognes beneficially own after this filing?
When was the RSU grant that vested for Steve Krognes originally made?
What is the vesting schedule for the RSU award reported by Steve Krognes?
Was any cash paid for the RSUs reported on the Form 4 for GH?
